source
- Federal court blocks mailing of mifepristoneLongevity "blue zones," an update on uterine transplant science, and more Morning Rounds health newsSTAT · 2mo ago↗ source
- STAT+: Biotech raises $42 million to run Huntington’s disease trialLatus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.STAT · 2mo ago↗ source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.BioPharma Dive · 2mo ago↗ source